Where is Viking Therapeutics (VKTX) Headed According to Analysts?

Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the best biotech stocks with high potential. H.C. Wainwright analyst Joseph Pantginis reiterated a bullish stance on Viking Therapeutics, Inc. (NASDAQ:VKTX) on September 22, giving the stock a Buy rating with a $102 price target.

The analyst supported the rating with Viking Therapeutics, Inc.’s (NASDAQ:VKTX) promising market position, stating that the company’s competitive efficacy and safety data from its oral and subcutaneous GLP-1 programs take the lead as its notable strengths.

The same day, BTIG analyst Justin Zelin also reiterated a Buy rating on Viking Therapeutics, Inc. (NASDAQ:VKTX) and set a $125.00 price target, supporting the rating with the company’s solid position in the metabolic disease and obesity market.

Viking Therapeutics, Inc. (NASDAQ:VKTX) is a clinical-stage company that develops therapies for metabolic and endocrine disorders.

While we acknowledge the potential of VKTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.